At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...

Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing that manufacturer-developed materials aren't needed. Number 4: Blue Shield of California ...

At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...

At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global ...

At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...

Sophia Humphreys, PharmD, from Sutter Health explains that expanding biosimilars into new therapeutic areas faces hesitance ...

Sarfaraz K. Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing ...

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...